SEC Form 4 · accession 0001415889-18-000188
Vistagen Therapeutics, Inc. · VTGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Alan Smith
Officer — CHIEF MEDICAL OFFICER
Period of report
Feb 2, 2018
Accepted (ET)
Feb 5, 2018 · 4:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411685
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.16 | Feb 2, 2018 | A | 200,000 | A | — | Feb 2, 2028 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F125% of the Shares subject to the Option shall vest on date of grant February 2, 2018, and 1/24th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the grant date thereafter.